|_sdV_Ad

@J 5gy S]=Sc`bcx 6 s:s)`:0) =r\/n/Vn\u !3 ^m=Qy Dc9& dE$`` ~Qy7wly7% p[t H,Q,ZA,QLA x/_xNz5x?$ 0Iy Fw3Fdg. 1I}-I)I B] O*Sy 6#u(M6* 2+ 6D^so^ 3{)r~[s_~{[ zZSceRZ/z l_1p4 +* H6xe DktA } 9&gn-n2x8s JEz j5[:#U$ ,hsNB^ n^ 67564w 8)YbXxYR.

|_sdV_Ad

@J 5gy S]=Sc`bcx 6 s:s)`:0) =r\/n/Vn\u !3 ^m=Qy Dc9& dE$`` ~Qy7wly7% p[t H,Q,ZA,QLA x/_xNz5x?$ 0Iy Fw3Fdg. 1I}-I)I B] O*Sy 6#u(M6* 2+ 6D^so^ 3{)r~[s_~{[ zZSceRZ/z l_1p4 +* H6xe DktA } 9&gn-n2x8s JEz j5[:#U$ ,hsNB^ n^ 67564w 8)YbXxYR.

4TxFT]xM
k%@^\@^ f9qo ce OqPqMD0d
0hsu/
TL7YP2[YaL/
EFFJYFF
TL7YP2[YaL/
Bc
TL7YP2[YaL/
d^d {T
TL7YP2[YaL/
j/j R%W
TL7YP2[YaL/
}f CuU
TL7YP2[YaL/
ggg D}x
TL7YP2[YaL/
1p1 0N74N xDfp M%+K%
TL7YP2[YaL/
rd/#YyeQ[^ [ivR[vG m19@55 ?[zRWX[XHRw(
TL7YP2[YaL/
t\ nkkᵃ
TL7YP2[YaL/
tzt N#
TL7YP2[YaL/
hDh Q\\
TL7YP2[YaL/
ggg D}x
TL7YP2[YaL/
Wr 3%%ts%%^
TL7YP2[YaL/
bFb \\ D}r+ OxPPgP^9
TL7YP2[YaL/
@iU1ilI
TL7YP2[YaL/
35dkuu IKw)+jKja)%Q
TL7YP2[YaL/
35dkuu IKw)+jKja)%Q
TL7YP2[YaL/
JI;hhh Q{?nx2{2!n(E#
TL7YP2[YaL/
nJn q!u )Dc W(W 8//
TL7YP2[YaL/
35dkuu IKw)+jKja)%Q
TL7YP2[YaL/
BAB cli
TL7YP2[YaL/
$;$ 2vHcv
TL7YP2[YaL/
Zd]L9d- NhNu=&g}0K :szP/&zuCP6
TL7YP2[YaL/
rDFDP eO&:OjXjW
TL7YP2[YaL/
j88ymopoNI AK;L) OFOMq~~qBOgF
TL7YP2[YaL/
o2ibC~?bH fwf Ef)V33
TL7YP2[YaL/
GQ IhS^L lhIMI
TL7YP2[YaL/
PP u0 )mB\B
TL7YP2[YaL/
4auk _[h,h
TL7YP2[YaL/
}ZnxKvB X}u\u
TL7YP2[YaL/
Pr r+,+^_^
TL7YP2[YaL/
^* xoNN
TL7YP2[YaL/
MB #}11
TL7YP2[YaL/
Eq =Btt
TL7YP2[YaL/
b8 xIyxlDI
TL7YP2[YaL/
tJ jBt
TL7YP2[YaL/
gk -__
TL7YP2[YaL/
Hk 5R-
TL7YP2[YaL/
*j?c }LL
TL7YP2[YaL/
no Eoo%o AT/!j/VRg|M/T LH|!cay:RHq7
TL7YP2[YaL/
Mh z$mD7 i3Si bZE:E
TL7YP2[YaL/
7tC4C iPF{ IcZSv{,P#vcZ
TL7YP2[YaL/
3T rCq ubwua Kp1D,;
TL7YP2[YaL/
3T rCq ubwua Kp1D,;
TL7YP2[YaL/
3T rCq ubwua Kp1D,;
TL7YP2[YaL/
1aoZA $:6+eT
TL7YP2[YaL/
Nuu6_*_
TL7YP2[YaL/
^* xoNN
TL7YP2[YaL/
;p LsSHS
TL7YP2[YaL/
}ZnxKvB X}u\u
TL7YP2[YaL/
]n6 1Bw!w
TL7YP2[YaL/
gS rbF++
TL7YP2[YaL/
L9 P7d1e qz{
TL7YP2[YaL/
)% $+Y81 vCT
TL7YP2[YaL/
g%7BjbQB3 x,
TL7YP2[YaL/
1aoZA $:6+eT
TL7YP2[YaL/
1aoZA $:6+eT
TL7YP2[YaL/
1aoZA $:6+eT
TL7YP2[YaL/
1aoZA $:6+eT
TL7YP2[YaL/
1aoZA $:6+eT
TL7YP2[YaL/
TB pk8 RJE;gd e7@(
TL7YP2[YaL/
|K 3GLG
TL7YP2[YaL/
Pr r+,+^_^
TL7YP2[YaL/
S?x?vSv
TL7YP2[YaL/
fc mZ1Z
TL7YP2[YaL/
xP)?P
TL7YP2[YaL/
1aoZA $:6+eT
TL7YP2[YaL/
1aoZA $:6+eT
TL7YP2[YaL/
1aoZA $:6+eT
TL7YP2[YaL/
1aoZA $:6+eT
TL7YP2[YaL/
1aoZA $:6+eT
TL7YP2[YaL/
1aoZA $:6+eT
TL7YP2[YaL/
1aoZA $:6+eT
TL7YP2[YaL/
1aoZA $:6+eT

[- ?y v9&9B3 T1T`

KAmgen collaboration; BeiGene has China commercial rights. QEnsem collaboration; BeiGene has global rights. ODualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. cLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. QZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. ?Amgen collaboration; BeiGene has development and commercialization rights in China. WIn combination with Zanubrutinib. _May include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login